Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Conduit Pharmaceuticals ( (CDT) ) is now available.
On May 15, 2025, Conduit Pharmaceuticals Inc. announced a 1-for-15 reverse stock split of its common stock, which was approved by stockholders on May 5, 2025. The reverse stock split will take effect on May 19, 2025, and the stock will begin trading on a split-adjusted basis on Nasdaq on May 20, 2025, under the ticker symbol ‘CDT’. This move is expected to consolidate the company’s shares, potentially impacting its stock price and market positioning.
More about Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc. is a dynamic, multi-asset clinical stage life science company focused on delivering an efficient model for compound development. The company acquires and funds the development of Phase 2-ready assets, utilizing an integrated platform driven by artificial intelligence and cybernetics, and aims for exits through third-party license deals following successful clinical trials.
Average Trading Volume: 3,081,343
Technical Sentiment Signal: Sell
Current Market Cap: $4.54M
Find detailed analytics on CDT stock on TipRanks’ Stock Analysis page.